Toshiaki Watanabe

Toshiaki Watanabe

Auto-generated profile, based on publicly available information

Toshiaki Watanabe

Center for Regenerative Medicine, National Center for Child Health and Development (NCCHD), Tokyo, Japan

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2017 in International Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
JRJapanese Society For Cancer Of The Colon And Rectum
Japanese Society For Cancer Of The Colon And Rectum
TWToshiaki Watanabe
Toshiaki Watanabe
KMKei Muro
Kei Muro
YAYoichi Ajioka
Yoichi Ajioka
YHYojiro Hashiguchi
Yojiro Hashiguchi
KSKenichi Sugihara
Kenichi Sugihara
Japanese mortality due to colorectal cancer is on the rise, surpassing 49,000 in 2015. Many new treatment methods have been developed during recent decades. The Japanese Society for Cancer of the Colon and Rectum Guidelines 2016 for the treatment of colorectal cancer (JSCCR Guidelines 2016) were prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines were prepared by consensus reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches, and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2016.

15 October 2011 in International Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TWToshiaki Watanabe
Toshiaki Watanabe
MIMichio Itabashi
Michio Itabashi
YSYasuhiro Shimada
Yasuhiro Shimada
STShinji Tanaka
Shinji Tanaka
YIYoshinori Ito
Yoshinori Ito
JRJapanese Society For Cancer Of The Colon And Rectum
Japanese Society For Cancer Of The Colon And Rectum
Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms in women and the third largest number in men. Many new treatment methods have been developed over the last few decades. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (JSCCR Guidelines 2010) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2010.

18 March 2015 in International Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TWToshiaki Watanabe
Toshiaki Watanabe
MIMichio Itabashi
Michio Itabashi
YSYasuhiro Shimada
Yasuhiro Shimada
STShinji Tanaka
Shinji Tanaka
YIYoshinori Ito
Yoshinori Ito
JRJapanese Society For Cancer Of The Colon And Rectum
Japanese Society For Cancer Of The Colon And Rectum
Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women and the third largest number among men. Many new methods of treatment have been developed during recent decades. The Japanese Society for Cancer of the Colon and Rectum Guidelines 2014 for treatment of colorectal cancer (JSCCR Guidelines 2014) have been prepared as standard treatment strategies for colorectal cancer, to eliminate treatment disparities among institutions, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding among health-care professionals and patients by making these guidelines available to the general public. These guidelines have been prepared as a result of consensuses reached by the JSCCR Guideline Committee on the basis of careful review of evidence retrieved by literature searches and taking into consideration the medical health insurance system and actual clinical practice in Japan. They can, therefore, be used as a guide for treating colorectal cancer in clinical practice. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions of the Guideline Committee, controversial issues were selected as clinical questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories, on the basis of consensus reached by Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2014.

9 January 2007 in Gut
Verified
Journal Article
Closed access
TKTsuyoshi Konishi
Tsuyoshi Konishi
TWToshiaki Watanabe
Toshiaki Watanabe
JKJunji Kishimoto
Junji Kishimoto
KKKenjiro Kotake
Kenjiro Kotake
TMTetsuichiro Muto
Tetsuichiro Muto
HNHirokazu Nagawa
Hirokazu Nagawa
Background: Colorectal carcinoids are often described as low-grade malignant. However, no study has compared the survival between patients with colorectal carcinoids and those with carcinomas, in a large series. In addition, no global consensus has been established on the crucial determinants of metastasis in colorectal carcinoids. Aim: To determine the predictive factors for metastasis in colorectal carcinoids and clarify their prognosis compared with adenocarcinomas. Methods: Data of all patients diagnosed as having colorectal carcinoids were extracted from a large nationwide database of colorectal tumours, the Multi-Institutional Registry of Large-Bowel Cancer in Japan, for the period from 1984 to 1998. Risk factors for lymph node (LN) metastases and distant metastases were analysed among those who were undergoing surgery, by univariate and multivariate analysis. Cancer-specific survival was also compared between patients with colorectal carcinoids and those with adenocarcinomas registered in the same period. Results: Among the 90 057 cases of colorectal tumours that were diagnosed, a total of 345 cases of carcinoids were identified, including 247 colorectal carcinoids of those undergoing surgery. Risk factors for LN metastasis were tumour size ⩾11 mm and lymphatic invasion, whereas those for distant metastasis were tumour size ⩾21 mm and venous invasion. Colorectal carcinoids without these risk factors exhibited no LN metastasis or distant metastasis. Cancer-specific survival of patients with colorectal carcinoids without metastasis was better than that of those with adenocarcinomas. However, the survival was similar between carcinoids and adenocarcinomas if the tumours had LN metastasis or distant metastasis. Conclusions: The presence of metastasis in colorectal carcinoids could lead to survival that is as poor as in adenocarcinomas. Tumours ⩽10 mm and without lymphatic invasion could be curatively treated by local resection, but others would need radical LN dissection.

1 March 2011 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
TWToshiaki Watanabe
Toshiaki Watanabe
TKTsuyoshi Konishi
Tsuyoshi Konishi
JKJunji Kishimoto
Junji Kishimoto
KKKenjiro Kotake
Kenjiro Kotake
TMTetsuichiro Muto
Tetsuichiro Muto
JRJapanese Society For Cancer Of The Colon And Rectum
Japanese Society For Cancer Of The Colon And Rectum

1 April 2006 in Cancer Research
Verified
Journal Article
Closed access
PDF file
TWToshiaki Watanabe
Toshiaki Watanabe
YKYasuhiro Komuro
Yasuhiro Komuro
TKTomomichi Kiyomatsu
Tomomichi Kiyomatsu
TKTakamitsu Kanazawa
Takamitsu Kanazawa
YKYoshihiro Kazama
Yoshihiro Kazama
HNHirokazu Nagawa
Hirokazu Nagawa
Preoperative radiotherapy has been widely used to improve local control of disease and to improve survival in the treatment of rectal cancer. However, the response to radiotherapy differs among individual tumors. Our objective here was to identify a set of discriminating genes that can be used for characterization and prediction of response to radiotherapy in rectal cancer. Fifty-two rectal cancer patients who underwent preoperative radiotherapy were studied. Biopsy specimens were obtained from rectal cancer before preoperative radiotherapy. Response to radiotherapy was determined by histopathologic examination of surgically resected specimens and classified as responders or nonresponders. By determining gene expression profiles using human U95Av2 Gene Chip, we identified 33 novel discriminating genes of which the expression differed significantly between responders and nonresponders. Using this gene set, we were able to establish a new model to predict response to radiotherapy in rectal cancer with an accuracy of 82.4%. The list of discriminating genes included growth factor, apoptosis, cell proliferation, signal transduction, or cell adhesion–related genes. Among 33 discriminating genes, apoptosis inducers (lumican, thrombospondin 2, and galectin-1) showed higher expression in responders whereas apoptosis inhibitors (cyclophilin 40 and glutathione peroxidase) showed higher expression in nonresponders. The present study suggested the possibility that gene expression profiling may be useful in predicting response to radiotherapy to establish an individualized tailored therapy for rectal cancer. Global expression profiles of responders and nonresponders may provide insights into the development of novel therapeutic targets. (Cancer Res 2006; 66(7): 3370-4)